The company, which largely remains in stealth mode, has set itself a mission of increasing the human lifespan by a decade.

Retro Biosciences, a US-based company focused on the cellular drivers of aging, has emerged with $180m in funding from undisclosed investors. The company was co-founded by Sheng Ding, who holds appointments at Gladstone Institutes, University of California (UC), San Francisco, Tsinghua University and Global Health Drug Discovery Institute. Retro remains in stealth mode – it…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.